{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029981","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.731490+00:00","generated_at":"2026-06-11T04:59:11.577319+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PowerUp Acquisition Corp. changes sponsor, board and officers; new CEO appointed","bullets":["New sponsor SRIRAMA Associates acquired 4,317,500 Class A shares and 6,834,333 warrants for $1 total.","All prior directors (Hack, Tretton, Blacklow, Uhrman, Campbell) and officers resigned.","Surendra Ajjarapu appointed CEO and Chairman; Howard Doss appointed CFO.","Trust account true-up payment of ~$0.02/share paid to redeeming shareholders on Aug 18, 2023.","New independent directors: Michael Peterson, Donald Fell, Mayur Doshi, Avinash Wadhwani."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029981","json":"https://secwatch.observer/filing/0001493152-23-029981.json","markdown":"https://secwatch.observer/filing/0001493152-23-029981.md","text":"https://secwatch.observer/filing/0001493152-23-029981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:59:11.577319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"147a5cb95b","claim":"Kyle Campbell resigned as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"1754990cc7","claim":"Michael L. Peterson was appointed as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"1b7699feaa","claim":"Gabriel Schillinger resigned as other_named_officer at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"1c7551ac89","claim":"Avinash Wadhwani was appointed as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"2dd4d23a09","claim":"Michael Olson resigned as other_named_officer at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"3ed2879423","claim":"Bruce Hack resigned as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"4c030aba6a","claim":"Jack Tretton resigned as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"5efe4303d1","claim":"Surendra Ajjarapu was appointed as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"6715df2bfd","claim":"Jack Tretton resigned as other_named_officer at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"76cc66155c","claim":"Peter Blacklow resigned as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"82bdd48a82","claim":"Donald G. Fell was appointed as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"90dbddbf41","claim":"Surendra Ajjarapu was appointed as Chairman of the Board at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(iv) Surendra Ajjarapu was appointed Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"9d0e470f36","claim":"Howard Doss was appointed as Chief Financial Officer at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(v) Surendra Ajjarapu and Howard Doss were appointed as the Company’s Chief Executive Officer and Chief Financial Officer, respectively (each, a “New Officer”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ae8e5c4681","claim":"Mayur Doshi was appointed as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"ce9a5ae785","claim":"Julie Uhrman resigned as director at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"dcbc043336","claim":"Surendra Ajjarapu was appointed as Chief Executive Officer at Aspire Biopharma Holdings, Inc..","evidence_excerpt":"(v) Surendra Ajjarapu and Howard Doss were appointed as the Company’s Chief Executive Officer and Chief Financial Officer, respectively (each, a “New Officer”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"448db70ff8edfea48b1355ed378a875436a1888a","claim":"Aspire Biopharma Holdings, Inc. entered into Purchase Agreement with PowerUp Sponsor LLC, SRIRAMA Associates, LLC valued at aggregate purchase price of $1.00 for 4,317,500 Class A ordinary shares and 6,834,333 private placem (effective 2023-08-18).","evidence_excerpt":"on July 14, 2023, PowerUp Acquisition Corp., a Cayman Islands exempted company (the “Company”), entered into a purchase agreement (the “Purchase Agreement”) with PowerUp Sponsor LLC, a Delaware limited liability company (the “Original Sponsor”) and SRIRAMA Associates, LLC, a Delaware limited liability company (the “New Sponsor”), pursuant to which the New Sponsor agreed to purchase from the Original Sponsor 4,317,500 Class A ordinary shares, of the Company and 6,834,333 private placement warrants, each exercisable for one Class A Ordinary Share for an aggregate purchase price of $1.00","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"PowerUp Sponsor LLC, SRIRAMA Associates, LLC"},{"label":"Value","value":"aggregate purchase price of $1.00 for 4,317,500 Class A ordinary shares and 6,834,333 private placem"},{"label":"Effective","value":"2023-08-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}